INTERVIEW | Dr James Campbell on Proactive


Patrys CEO and MD, Dr James Campbell, was interviewed by Andrew Scott from Proactive about new preclinical data for its full-sized IgG antibody, PAT-DX3, showing that it can cross the blood-brain barrier in healthy animals.

“These properties open up a range of applications for using deoxymabs to deliver small molecule therapeutics and gene editing technologies directed to various neurological targets and conditions,” said Dr Campbell.

Watch the interview here.